Hester Biosciences share price, P/E, ROE & financials

Hester Biosciences (HESTERBIO) had a P/E of 14.7× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 12% below their 52-week high. Sales and net profit grew 7.7% and 28% a year over 3 years, with ROCE of 16% and ROE of 16%, though net profit is above operating profit, which points to a one-off gain. Debt is 0.53× equity, and its dividend yield is 0.5%. It is a small-cap company with a market cap of ₹2,017 Cr, ranked 58th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 50% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹2,421.30
Day high: ₹2,440.20
Day low: ₹2,325.00
Prev. close: ₹2,407.30
Volume: 5.4K

Health check

1 good · 3 fair · 1 to check

ReturnsAhead
+50.1% over a year, better than 6 of 7 peers.
Price tagDistorted
A one-off gain inflates profit, so P/E isn’t comparable right now.
GrowthSteady
Sales +7.7%, profit +27.8% a year over 3 years.
ProfitabilityAverage
ROCE 15.8% vs peer median 17.9%.
Balance sheetFair
Debt 0.53× equity, interest covered 11.2×, Piotroski 8 of 9.
Red flags3 to check
Quarterly sales down 8.2% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹2,017 Cr, #58 of 154 in its industry by size.

Defensive

Beta 0.36 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹327 Cr · profit ₹136 Cr

Market cap: ₹2,017 Cr; Small cap
P/E: 14.7; Industry 28.7
Price to book: 5.60; Peers 4.99
Dividend yield: 0.46%
ROE: 16.5%; Peers 14.7%
ROCE: 15.8%; Peers 17.9%
Debt to equity: 0.53; Debt ₹195 Cr
EPS (TTM): ₹160.95; Face value ₹10
OPM (TTM): 26.6%; Net margin 41.6%
Sales growth: −8.2%; Latest quarter vs a year ago
Profit growth: +489.8%; Latest quarter vs a year ago
Price to sales: 6.16; EV/EBITDA 27.9

Strengths

Quarterly profit up 489.8% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

Quarterly sales down 8.2% on a year ago.
Net profit is above operating profit, so a one-off gain is likely flattering earnings.
Promoter stake down from 53.7% to 44.3%.

Derived automatically from reported figures. Not a recommendation.

About Hester Biosciences

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for…

Headquarters: Mehsana
Employees: 483
Sector: Healthcare
ISIN: INE782E01017
Website: hester.in

Price range

52 weeks

₹1,239.30₹2,683.60

Today

₹2,325.00₹2,440.20

Avg volume (3M): 5.9K
1-year return: plus 50.1%
From 52-week high: minus 11.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.87%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.30%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.81%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.59%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.93%	minus 6.6%
HESTERBIOHester Biosciences	2,371.40	minus 1.49%	2,017	14.7	5.60	15.8%	16.5%	26.6%	7.7%	27.8%	0.46%	plus 50.1%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.59%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
84.1	71	77.4	100	77.2
61.3	59.3	59.6	65.8	54.5
22.8	11.7	17.8	34.3	22.8
27.1%	16.5%	23.0%	34.3%	29.5%
3.4	11.9	2	−1.2	3.7
1.8	2.2	1.8	5.1	3.1
4.2	4.4	4.4	5.9	7
–	–	–	2.9	–
20.2	17	13.5	25.1	16.3
14.3%	15.9%	31.2%	34.0%	30.3%
16.4	14.4	8.8	16	97
20.33	16.85	10.94	19.45	113.71

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +7.7%
Profit CAGR 3Y: +27.8%
EPS CAGR 3Y: +27.8%
ROE: 16.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
266	305	311	333
–	+14.5%	+2.2%	+6.9%
204	245	249	237
62.3	59.5	62	96
23.4%	19.5%	19.9%	28.9%
4.1	−1.9	3.2	10
5.1	9.1	8.3	7.4
20.7	17.2	16.8	18.9
−0.3	0.7	−0.5	−3.8
40.2	32	39.6	75.8
30.2%	33.8%	27.2%	24.2%
26.6	18.9	27.5	55.6
–	minus 29.1%	+45.5%	+102.4%
31.30	22.20	32.31	65.40

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
8.5	8.5	8.5	8.5
271	283	306	352
274	244	213	195
116	126	126	123
670	662	653	678
409	410	411	414
150	170	178	2.5
13.8	13	6.5	2.9
96.9	69.6	57.6	259
670	662	653	678

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
23.6	48.2	64.5	64.1
−77	−22.6	−19	−2.9
41.8	−26.1	−51.7	−48.8
−11.6	−0.5	−6.2	12.5
−77.8	−24.4	−20.6	−17.8
−54.2	23.8	43.9	46.3
−8.5	−6.9	−5.2	−6

Shareholding pattern

Source: NSE filings

44.3%

promoters

Promoters44.28%
Public55.72%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	44.28%	55.72%	minus 9.45
30 Jun 2026	53.73%	46.27%	0.00
31 Mar 2026	53.73%	46.27%	0.00
31 Dec 2025	53.73%	46.27%	0.00
30 Sep 2025	53.73%	46.27%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you